Rocket Pharmaceuticals (RCKT) FDA announcement summary

Introduction and purpose

• FDA granted accelerated approval to KRESLADI, the first gene therapy for severe leukocyte adhesion deficiency type I (LAD-I) in pediatric patients, addressing a high unmet medical need and high early-childhood mortality.

• KRESLADI is indicated for children with severe LAD-I due to biallelic ITGB2 mutations who lack an HLA-matched sibling donor.

Details of approval or decision

• Approval was granted under the FDA's accelerated approval pathway based on biomarker restoration of neutrophil CD18 and CD11a expression; continued approval depends on confirmatory trials.

• The approval makes the company eligible for a Rare Pediatric Disease Priority Review Voucher (PRV), which may provide non-dilutive capital and incentivize further rare disease therapy development.

Impact on industry and stakeholders

• KRESLADI is the first and only gene therapy approved for severe LAD-I, marking a milestone for the severe LAD-I and broader primary immunodeficiency communities.

• Families and clinicians gain a new treatment option for a disease with limited alternatives.

• Commercialization will initially focus on the U.S. market, with no immediate plans for international expansion.